Top Content

view more
article-block

Precision medicine and the role of pathologists in multidisciplinary bladder cancer care

How can the combined power of multidisciplinary teams and precision medicine be harnessed for people living with bladder cancer?

 5 September 2024
article-block

Sustainable drug delivery devices: striking a balance between aspirations and current possibilities

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

 17 July 2024
article-block

Exploring disease modification to change the future of epilepsy treatment

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

 17 July 2024
article-block

The role of AI in patient support

Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise

 17 July 2024
article-block

Pride month and LGBTQ+ healthcare

Betsy Goodfellow from Pharmafocus considers Pride month and the state of LGBTQ+ healthcare in the UK

 4 June 2024
article-block

European Commission approves Pfizer’s Velsipity for ulcerative colitis treatment

Pfizer has announced that the EC has granted marketing authorisation for Velsipity (etrasimod) in the EU.

 4 March 2024

Industry Insights

view more
article-block

Sustainable drug delivery devices: striking a balance between aspirations and current possibilities

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

 17 July 2024
article-block

Exploring disease modification to change the future of epilepsy treatment

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

 17 July 2024
article-block

The role of AI in patient support

Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise

 17 July 2024
article-block

20 years of EGFR in NSCLC: how precision medicine helps navigate lung cancer challenges

Henar Hevia at Johnson & Johnson considers the progress that has been made in lung cancer treatment since the discovery of EGFR, including the evolving treatment paradigm, the role of precision medicine in treatment decision-making and quality of life for patients receiving targeted treatments

 4 June 2024
article-block

Paediatric clinical trials for obesity treatment

Alan Baldridge and Heather Peterson from ICON consider the prevalence of paediatric obesity and assess clinical trials of its treatments

 4 June 2024
article-block

Epilepsy and brain health: a call for global action and unity

Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment

 28 April 2024

UK News

view more
article-category

CluePoints launches Medical & Safety Review (MSR) software

Risk-based quality management (RBQM) and data quality oversight software company Cluepoints launches its latest application, the medical & safety review (MSR), to simplify and streamline the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history.

article-category

Next-generation sequencing partnership announced between ANGLE plc and NuProbe

Liquid biopsy company ANGLE plc has announced a partnership with NuProbe, a genomics and molecular diagnostics company, to utilise the latter’s pan-cancer next-generation sequencing (NGS) panel.

article-category

FDA approves first drug in 50 years for treatment of schizophrenia in adults

Earlier this September, the US Food and Drug Administration (FDA) granted approval for PureTech Health’s Karxt for the treatment of schizophrenia in adults, triggering royalty payments of $29m to PureTech. It will be the first approved mechanism by the FDAfor schizophrenia in over 50 years.

article-category

Research collaboration between FDA and Owlstone Medical set to see improvements in breath biopsies

Owlstone Medical has entered into a research collaboration with the US Food and Drug administration’s (FDA) centre for devices and radiological health to develop methods for the confident identification of individual chemicals in the composure of breath.

article-category

First nasal spray for treatment of anaphylaxis approved by FDA

Ars pharmaceuticals has been granted approval by the us food and drug administration (fda) for their epinephrine nasal spray, neffy, to be used as treatment of type 1 allergic reactions including anaphylaxis.

article-category

Novo Holdings invests in Oxford Nanopore Technologies

Leading life science investor novo holdings has announced a £50m investment in oxford nanopore technologies. Oxford nanopore technologies is a leading uk-listed company currently specialising in a new generation of molecular sensing technology based on nanopores.

article-category

Cresset collaborates with Enamine to enable the design of new targeted protein degraders

Drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research organisation (cro) Enamine.

article-category

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

Accord healthcare have recently announced that NICE have recommended the first oral androgen deprivation therapy (adt) treatment for hormone-sensitive prostate cancer. Prostate cancer is the most common cancer in men across the uk.

article-category

Verisense announce opening of Digital Biobank

This month, Verisense have announced that their digital biobank, with data from over one million people, is open for business.

article-category

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

Biotechnology company Levicept has announced positive results from its phase 2 trial into levi-04 for the treatment of osteoarthritis.

article-category

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

Calliditas therapeutics ab has recently announced that the phase 2b transform trial met its primary endpoint. The trial showed statistically significant improvement in alkaline phosphatase (alp) for both doses tested versus placebo. the trial evaluated setanaxib, a nox enzyme inhibitor, in patients with primary biliary cholangitis (pbc) and elevated liver stiffness.

article-category

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

Merck (known as MSDoutside of the US and Canada) has announced that its anti-pd-1 therapy, in combination with padcev (enfortuman vedotin-ejfv), has received a positive opinion from the European Medicines Agency (EMA)

article-category

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young

Researchers at the UCLA Health jonsson comprehensive cancer center have announced that they are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine. The vaccine targets h3 g34-mutant diffuse hemispheric glioma, an aggressive brain tumour typically found in adolescents and young people.

article-category

The National Institute for Health and Care Excellence announce technology appraisal guidance

The National Institute for Health and Care excellence (NICE) have recommended adult patients in England or Wales with moderately or severely active ulcerative colitis (uc) who have not responded well to or cannot tolerate conventional or biological therapy including a tumour necrosis factor (tnf) alpha inhibitor the option of skyrizi (risankizumab).

article-category

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated

This month, Janssen-Cilag international, part of johnson & johnson (j&j) has announced that the European Commission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (nsclc) with an epidermal growth factor receptor (EGFR).

article-category

Eisai and EcoNaviSta enter dementia collaboration

Eisai and Econavista have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build an ecosystem in the field of dementia.

Global News

view more
article-category

NICE gives positive recommendation for Santen’s Roclanda

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Santen’s Roclanda (netarsudil 0.02% and latanoprost 0.005%) as an option for patients suffering from primary open-angle glaucoma (poag) or ocular hypertension.

article-category

CHMP adopts positive opinion for new breast cancer drug, Kisquali, from Novartis

Last month, the Committee for Medicinal Products for Human Use (CHMP), which is part of the European Medicines Agency (EMA) announced that it has adopted a positive opinion for Novartis’ Kisquali (ribociclib) as an adjuvant in the treatment of adults with hormone receptor-positive/human epidermal growth factor 2negative (hr+/her2-) early breast cancer (ebc).

article-category

Eplontersen recommended for EU approval by CHMP for hereditary transthyretin-mediated amyloidosis

Wainzua (Eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the EU by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP). The drug will be used as a treatment for hereditary transthyretin-mediated amyloidosis in adult patients who have stage 1 or 2 polyneuropathy (commonly referred to as hattr-pn or attrv-pn).

article-category

CytexOrtho receives FDA greenlight for clinical trials into joint repair technology

Clinical stage medical device company CytexOrtho has announced approval from the US Food and Drug Administration (FDA) for its planned phase 1 clinical trial into orthopaedic joint preservation and repair.

article-category

Survey from Roche finds worryingly low understandings about HPV and cervical cancer

Questioning almost 9,000 participants across 12 countries in Latin America and Europe, the research revealed significant knowledge gaps surrounding human papillomavirus (HPV) and highlighted several significant barriers preventing women from screening for it.

article-category

Best-in-class AI model from Bioptimus integrated into Proscia’s leading software platform

French start-up Bioptimus has announced that its H-optimus-o biology reference artificial intelligence (AI) foundation model has been wholly integrated into Proscia’s Concentriq Embeddings software platform, with the aim of enabling quicker and more efficient breakthroughs in AI development for therapeutic research.

article-category

HIV vaccine candidate successfully optimised for industrial production

Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV)-1 vaccine candidate (SAV0001) at bench scale.

article-category

Aravax successfully recruits for phase 3 peanut allergy treatment study

Clinical-stage biotech company Aravax has announced that it has completed phase 2 recruitment for its precision therapy (pvx108) study, which investigates treatment of peanut allergies.

article-category

Headlands Research opens new clinical trials site in El Paso, Texas, to serve Hispanic population

Headlands Research, a multinational network of clinical research sites, has launched a new clinical trials site in El Paso, Texas, US.

article-category

Biologic medicine Dupixent approved by FDA for COPD patients in the US

The US Food and Drug Administration has approved Sanofi’s Dupixent as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.

article-category

Tiziana Life Sciences awarded $4m grant by NIH to study anti-CD3 in Alzheimer’s disease

Tiziana Life Sciences, a biotechnology company developing immunomodulation therapies, announced that the National Institutes of Health (NIH),'s National Institute on Aging has awarded a $4m grant to Dr Howard Weiner as principal investigator at Brigham and Women’s Hospital to be the key research site to study nasal anti-cd3 for the treatment of alzheimer’s disease (ad).

article-category

European Commission approves Astellas Pharma’s GEJ adenocarcinoma treatment

The European Commission (EC) has approved Astellas Pharma’s vyloy (zolbetuximab) in combination with fluoropyrimidine and platinum-containing chemotherapy as a treatment for adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are claudin (CLDN) 18.2 positive.

article-category

Ministry of Health, Labour and Welfare of Japan approves new drug for early Alzheimer’s disease

The Ministry of Health, Labour and Welfare Japan has approved treatment for Eli Lilly’s KINSULA, indicated for adult patients with early symptomatic Alzheimer’s disease (AD). This also includes patients with mild dementia stage AD, and mild cognitive impairment.

article-category

New collaboration agreement announced between EMIH association and the MTIG

The European Microbiome Innovation for Health (EMIH) association and the Microbiome Therapeutics Innovation Group (MTIG) have announced a new collaborative agreement. The agreement seeks to advance microbiome drug development by improving collaboration between the two microbiome focused coalitions.

article-category

FDA approves first drug in 50 years for treatment of schizophrenia in adults

Earlier this September, the US Food and Drug Administration (FDA) granted approval for PureTech Health’s Karxt for the treatment of schizophrenia in adults, triggering royalty payments of $29m to PureTech. It will be the first approved mechanism by the FDAfor schizophrenia in over 50 years.

article-category

Third application for Orion’s prostate cancer drug submitted by partner Bayer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, darolutamide, in the US.

European News

view more
article-category

Survey from Roche finds worryingly low understandings about HPV and cervical cancer

Questioning almost 9,000 participants across 12 countries in Latin America and Europe, the research revealed significant knowledge gaps surrounding human papillomavirus (HPV) and highlighted several significant barriers preventing women from screening for it.

article-category

Best-in-class AI model from Bioptimus integrated into Proscia’s leading software platform

French start-up Bioptimus has announced that its H-optimus-o biology reference artificial intelligence (AI) foundation model has been wholly integrated into Proscia’s Concentriq embeddings software platform, with the aim of enabling quicker and more efficient breakthroughs in ai development for therapeutic research.

article-category

Almirall’s Immunoskin event returns for a third year, discussing medical dermatology advances

Hosted again in Barcelona, Spain, the Immunoskin conference ran from 26-27 October and brought together leading experts in dermatological conditions and treatments.

article-category

EcoVadis Platinum medal given to Liveo Research’s Singapore pharma packaging site

Liveo Research, a leading primary packaging manufacturer, has had the EcoVadis rating of its Singapore site increased from gold to platinum. This means that the pharma packaging site is now rated in the top 1% of the 100,000 companies evaluated by ecovadis in its annual global surveys.

article-category

HUTCHMED set to receive $20m in funding from Takeda for colorectal cancer drug sales

In late October, HUTCHMED’s partner Takeda will pay a milestone payment of $20m as the result of over $200m worth of sales for Fruzaqla (fruquintinib), which treats metastatic colorectal cancer (CRC).

article-category

Exhibitor numbers for CPHI India grow for third year in a row, with 50,000 attendees expected

Running from 26-28 November 2024, the largest pharma event in India is expected to have a record attendance of delegates from more than 150 countries, with over 2,000 exhibitors also expected.

article-category

PacBio announces update to sequencing system to bring down cost of genome sample to below $500

Announced by PacBio, known for developing sequencing solutions, SPRQ has the potential to significantly reduce the cost of sequencing genomes.

article-category

HIV vaccine candidate successfully optimised for industrial production

Sumagen Canada Inc, a biotech company based in both South Korea and Canada, has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV)-1 vaccine candidate (sav0001) at bench scale.

article-category

Bayer and Liveo Research pair to launch new sustainable blister packaging

The partnership between the two companies has resulted in the launching of a first-of-its-kind blister packaging, utilising polyethylene terephthalate (PET) instead of the more traditional poly vinyl chloride (PVC).

article-category

NRG Therapeutics secures funding for development of treatment for neurodegenerative disease

NRG Therapeutics has announced that its NRG5051 inhibitor has secured a $5m grant from the Michael J. Fox foundation for Parkinson’s research (MJFF).

article-category

PacBio announces update to sequencing system to bring down cost of genome sample to below $500

Announced by PacBio, known for developing sequencing solutions, SPRQ has the potential to significantly reduce the cost of sequencing genomes.

article-category

Bayer and Liveo Research pair to launch new sustainable blister packaging

The partnership between the two companies has resulted in the launching of a first-of-its-kind blister packaging, utilising polyethylene terephthalate (PET) instead of the more traditional poly vinyl chloride (PVC).

article-category

Aravax successfully recruits for phase 3 peanut allergy treatment study

Clinical-stage biotech company Aravax has announced that it has completed phase 2 recruitment for its precision therapy (pvx108) study, which investigates treatment of peanut allergies.

article-category

NRG Therapeutics secures funding for development of treatment for neurodegenerative disease

NRG Therapeutics has announced that its NRG5051 inhibitor has secured a $5m grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).

article-category

Chiesi announces phase 3 results from enzyme-replacement study

Chiesi Global Rare Diseases has announced the results from its BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug ELFABRIO at twice the approved dose in patients who have been treated with agalsidase alfa or beta.

article-category

VALIANT phase 3 trial results highlight potential treatment for rare kidney diseases

SOBI and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit patients with c3 glomerulopathy (c3g) and primary immune complex membranoproliferative glomerulonephritis (ic-mpgn).

How to Install

Appointments

view more
article-category

Darrin Schellin appointed new CEO at Pharma Tech Industries

Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of its new chief executive officer, Darrin T Schellin.

article-category

CluePoints appoint Richard Young as chief strategy officer

Cluepoints, a data quality oversight and and risk-based quality management software provider, has announced the appointment of Richard Young as its chief strategy officer.

article-category

Dr Souad Kechairi appointed chief medical officer at PLL Therapeutics

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

article-category

Shawn Cross appointed as chief financial officer for Pacira Biosciences

Pacira biosciences, specialist in non-opioid pain therapies, has appointed Shawn Cross as its chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations.

article-category

Dr Souad Kechairi appointed chief medical officer at PLL Therapeutics

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

article-category

Prilenia appoints new staff to advance company’s development plans

Prilenia, a clinical stage biotech focusing on neurodegenerative and neurodevelopmental disorders, has announced the appointment of two new senior staff members ‒ Rob Lauzen as chief financial officer (CFO) and Jason Marks as chief legal officer (CLO).

article-category

Steriline’s founder ‘passes torch’ to children with CEO and CSO appointments

Aseptic packaging company Steriline’s founder Gerardo Fumagalli has ‘passed the torch’ to his children Illaria Fumagalli and Federico Fumagalli, who have been appointed to chief executive officer and chief sales officer, respectively. Gerardo will continue on as chairman of the board of directors.

article-category

Eli Lilly expands with two senior hires in Public Affairs and Communications team

Pharmaceutical company Eli Lilly has announced the appointment of two senior positions in its public affairs and communications team.

article-category

Dr Anada Gubbi appointed by SFA Therapeutics as director of Biostatistics

SFA Therapeutics, a clinical-stage biopharmaceutical company, has announced that it has appointed Dr Anada Gubbi as director of biostatistics. Dr Gubbi will be responsible for assisting SFA Therapeutics in effectively developing drug candidates for the treatment of inflammatory diseases.

article-category

Curve Therapeutics bolsters its leadership team with appointment of Simon Jones

With his 20 years of expertise and proven track record in biotech and pharmaceutical industries, Curve Therapeutics appoints Simon Jones as chief financial officer and chief operating officer.

article-category

Adam Rosenberg replaces Dr Carlo Incerti as new chair of the board at VectorY Therapeutics

Vectory Therapeutics has announced the appointment of Adam Rosenberg as chair of the board, replacin Dr Carlo Incerti.

article-category

Dr Jonathan Appleby appointed by Mogrify as chief scientific officer

Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer.

article-category

Professor yih-shing duh appointed as chief scientific advisor by H.E.L. Group

Professor Yih-Shing Duh appointed as chief scientific advisor by H.E.L. Group

article-category

Enhanc3D Genomics appoints Hazel Jones as CEO

Enhanc3D Genomics has announced the appointment of Hazel Jones as chief executive officer (CEO), following a successful six-month term as interim CEO and COO.

article-category

Closed Loop Medicine appoints Paul Johnson as non-executive director

Closed loop medicine has announced the appointment of Paul Johnson as an independent non-executive director.

article-category

Sphere Fluidics appoints Curtis Nicholson as director of sales EMEA

Sphere Fluidics has announced the appointment of Curtis Nicholson as director for sales for Europe, Middle East and Africa (EMEA).